- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03640325
The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation
January 8, 2024 updated by: Abby Rosenberg, Seattle Children's Hospital
Multisite Randomized Controlled Trial (RCT) testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults receiving hematopoietic cell transplantation for hematology malignancy.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The experience of hematopoietic cell transplantation (HCT) for malignancy or cancer predisposition among Adolescents and Young Adults (AYAs) is particularly difficult because age-related developmental challenges of identity, relationships, and vocation may add to the burden of cancer.
Compared to other age-groups, AYAs have poorer psychosocial outcomes including increased anxiety and depression and poorer adherence to oral immunosuppressive medications.
These outcomes may, in turn, predispose AYAs to disease-related morbidity and mortality such as graft-versus-host disease (GVHD) and/or cancer-relapse.
A potential barrier to improving these experiences may be that AYAs have few opportunities to develop the personal resources needed to handle adversity.
We have previously developed the "Promoting Resilience in Stress Management" (PRISM) intervention for AYAs with serious illness.
This manualized, brief intervention is delivered in 4, 30-60 minute, one-on-one sessions, followed by a Parent/ Caregiver/ Spouse/ significant other inclusive meeting.
It targets skills in stress-management and mindfulness, goal-setting, positive reframing, and meaning-making.
All of these skills are associated with improved patient well-being in other populations, and preliminary findings from a recently closed phase II randomized controlled trial among AYAs with newly diagnosed cancer suggest PRISM is associated with improved health-related quality of life.
This study will build on our prior experience and fill a critical knowledge gap regarding PRISM's impact among AYAs receiving HCT.
Thus, we will conduct a multi-site randomized controlled trial with the primary trial outcome of patient-reported symptoms of anxiety and depression.
Secondary and exploratory outcomes will include the cost-effectiveness of the intervention in this population, the impact of the intervention on parent well-being, and patient adherence to oral graft-versus-host-disease medications.
We hypothesize that AYAs who receive PRISM will report fewer mixed affective symptoms, while their parents report improved quality of life and psychological distress.
We also anticipate the intervention will positively impact adherence and be cost-effective.
In sum, this study offers an opportunity to expand the body of knowledge regarding methodologically rigorous and evidence-based psychosocial interventions and standards of care for AYAs with hematologic malignancies.
Ultimately, this research has the potential to reduce the burden of cancer in these vulnerable populations.
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama, Birmingham
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital of Los Angeles
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber/Harvard Cancer Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Washington
-
Seattle, Washington, United States, 98145
- Seattle Children's Hospital Cancer and Blood Disorders Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 24 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient aged 12-24 years
- Receiving hematopoietic cell transplantation (HCT) for malignancy or cancer predisposition syndrome
- Within 4 weeks of HCT "day zero"
- Able to speak English
- Able to read English or Spanish
- Cognitively able to participate in interviews
Exclusion Criteria:
- Patient refusal
- Cognitively or physically unable to participate in interviews
- Unable to speak English
- Unable to read English or Spanish
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRISM (Promoting Resilience in Stress Management)
Resilience Skills Training
|
Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
|
No Intervention: Usual Care
Usual psychosocial care (control arm, no intervention)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital Anxiety & Depression Scale Score - Depression sub-score
Time Frame: 6-months
|
The HADS assesses mixed affective symptoms in patients with serious illness.
The scale consists of 7 questions for anxiety and 7 for depression.
Each is scored from 0-3, for a total range of 0-21 points per subscale.
"Caseness" of anxiety and depression is defined as ≥8 points, with sensitivity/specificity of 0.8/0.9 for anxiety and 0.8/0.8 for depression.
The depression sub-scale will be measured as a continuous variable.
|
6-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Memorial Symptom Assessment Scale Score
Time Frame: 6-months
|
The MSAS measures the presence, severity, frequency, and extent of bother from 32 symptoms Likert scales assess physical and psychological symptoms.
Total- and sub-scores are calculated as an average and normalized to a scale of 0-100, with higher scores representing higher symptom burden.
|
6-months
|
PedsQL Generic Core and Cancer-Related Quality of Life Score
Time Frame: 6-months
|
The PedsQL 4.0 Generic and 3.0 Cancer Module include 50 items evaluating health-related quality of life of AYAs with cancer.
Items are rated on a 5-point Likert scale and total scores transformed to a 0-100 scale with higher scores representing better HRQOL.
Internal consistency ranges from 0.75 to 0.92.
|
6-months
|
Connor-Davidson Resilience Scale
Time Frame: 6-months
|
The Connor-Davidson Resilience Scale (CD-RISC) measures inherent resiliency.
Two items from the original 25-item CD-RISC were used to create a brief, 2-item scale (the CD-RISC2), namely items 1 ("Able to adapt to change") and 8 ("Tend to bounce back after illness or hardship").
Each item consists of a 5-point Likert scale (scored from zero to four).
The 2-item scale has a total of 10 points, with higher scores reflecting greater perceived resilience.
|
6-months
|
Hope Scale Scores
Time Frame: 6-months
|
The Snyder "Hope" Scale measures "the overall perception that one's goals can be met."
The instrument scored on an 8-point Likert scale (score range 0-64).
Higher scores imply greater levels of hopeful thought patterns.
|
6-months
|
Parent Generalized Anxiety Disorder (GAD-7 scores)
Time Frame: 6-months
|
Parent Anxiety: This 7-item survey is commonly used to identify cases of generalized anxiety disorder and to assess symptom severity.
GAD-7 score range from 0 to 21, with scores of ≥5, ≥10, and ≥15 representing mild, moderate, and severe anxiety symptoms levels, respectively.
|
6-months
|
Parent Depression (PHQ-8 scores)
Time Frame: 6-months
|
Parent Depression: This 8-item survey is scored on a 4-point Likert scale and the sum (0- 27) indicates the degree of depression, with scores of ≥5, ≥10, and ≥15 representing mild, moderate, and severe depression.
|
6-months
|
Parent quality of life (SF-36 scores)
Time Frame: 6-months
|
The SF-36 incorporates 8 concepts: physical functioning, body pain, limitations due to physical health problems, role limitations due to personal or emotional problems as well as emotional well-being and social functioning, energy, fatigue and general health perceptions.
Scores will be summed and normalized to a 100 point (0-100) scale, with higher scores indicating higher quality of life.
|
6-months
|
Hospital Anxiety and Depression Scale - Anxiety sub-score
Time Frame: 6-months
|
The HADS assesses mixed affective symptoms in patients with serious illness.
The scale consists of 7 questions for anxiety and 7 for depression.
Each is scored from 0-3, for a total range of 0-21 points per subscale.
"Caseness" of anxiety and depression is defined as ≥8 points, with sensitivity/specificity of 0.8/0.9 for anxiety and 0.8/0.8 for depression.
The anxiety sub-scale will be measured as a continuous variable.
|
6-months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of PRISM on heart-rate variability
Time Frame: 6-months
|
Exploratory aim: A subset of patients will participate in an optional companion study to evaluate the impact of PRISM on Heart Rate Variability as a biomarker of stress
|
6-months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Abby R Rosenberg, MD, MS, MA, Dana-Farber Cancer Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2019
Primary Completion (Actual)
March 31, 2023
Study Completion (Estimated)
March 31, 2024
Study Registration Dates
First Submitted
August 15, 2018
First Submitted That Met QC Criteria
August 17, 2018
First Posted (Actual)
August 21, 2018
Study Record Updates
Last Update Posted (Actual)
January 10, 2024
Last Update Submitted That Met QC Criteria
January 8, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00001077 (SC-N126)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
All IPD will be protected and maintained by the study team
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Charite University, Berlin, GermanyCompletedTreatment Resistant Depression | Depression, Unipolar | Depression ChronicGermany
Clinical Trials on PRISM (Promoting Resilience in Stress Management)
-
Seattle Children's HospitalCompletedSarcoma | Lymphoma | Cancer | Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Brain Tumors | Germ Cell TumorUnited States
-
University of WashingtonNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingCommunication | Chronic Illness | Discrimination, Racial | Bias, RacialUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Baylor College of Medicine; Seattle Children... and other collaboratorsActive, not recruitingDepression | Quality of Life | Cancer | Anxiety | Communication | Coping Skills | HopeUnited States
-
Seattle Children's HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting
-
Seattle Children's HospitalCompleted
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCongenital Heart DiseaseUnited States
-
Seattle Children's HospitalUniversity of Pittsburgh Medical CenterNot yet recruitingCancer | Coping Skills | Psychosocial Functioning | Social Functioning
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS); North American...RecruitingMitochondrial Diseases | Mitochondrial Myopathies | MELAS | Mitochondrial Encephalomyopathies | MERRFUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)RecruitingStress | AnxietyUnited States
-
University of Alabama at BirminghamRecruiting